SAN FRANCISCO—After securing FDA clearance for its G7 continuous glucose monitor system last month, Dexcom is ready to begin adding the U.S. to its list of launch sites across the globe this quarter.
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
DexCom is handing over shares in itself to Google as part of a new blood glucose monitoring collaboration. Improving care There are 387 million diabetic people worldwide and that number is estimated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback